TABLE 3.
Model 1 a | Model 2 a | |||||||
---|---|---|---|---|---|---|---|---|
Aβ42 (60/209) d (60/208) e | OR | 95% CI | S.E | P‐value | OR | 95% CI | S.E | P‐value |
Western | 1.30 | 0.95;1.78 | 0.16 | .10 | 1.30 | 0.90;1.89 | 0.19 | .17 |
Mediterranean/prudent | 0.99 | 0.74;1.32 | 0.15 | .94 | 0.89 | 0.65;1.23 | 0.16 | .49 |
High‐protein and alcohol | 0.98 | 0.73;1.31 | 0.15 | .88 | 0.84 | 0.59;1.19 | 0.18 | .33 |
High‐total and saturated fat | 0.98 | 0.74;1.29 | 0.14 | .87 | 0.89 | 0.66;1.20 | 0.15 | .44 |
OR | 95% CI | S.E | P‐value | OR | 95% CI | S.E | P‐value | |
---|---|---|---|---|---|---|---|---|
Western | 1.22 | 0.92;1.64 | 0.15 | .17 | 1.25 | 0.88;1.76 | 0.18 | .21 |
Mediterranean/prudent | 1.06 | 0.81;1.38 | 0.14 | .67 | 0.90 | 0.67;1.21 | 0.15 | .48 |
High‐protein and alcohol | 0.92 | 0.70;1.20 | 0.14 | .53 | 0.80 | 0.58;1.12 | 0.17 | .19 |
High‐total and saturated fat | 0.96 | 0.74;1.24 | 0.13 | .76 | 0.90 | 0.68;1.19 | 0.14 | .45 |
Aβ42+Tau c (27/242) d (27/241) e | OR | 95% CI | S.E | P‐value | OR | 95% CI | S.E | P‐value |
---|---|---|---|---|---|---|---|---|
Western | 1.81 | 1.14;2.86 | 0.23 | .01 | 1.79 | 1.03;3.10 | 0.28 | .04 |
Mediterranean/prudent | 1.01 | 0.68;1.15 | 0.20 | .95 | 0.92 | 0.60;1.41 | 0.22 | .70 |
High‐protein and alcohol | 0.96 | 0.64;1.44 | 0.21 | .86 | 0.68 | 0.42;1.12 | 0.25 | .13 |
High‐total and saturated fat | 1.15 | 0.79;1.68 | 0.19 | .47 | 1.03 | 0.68;1.56 | 0.21 | .88 |
T‐tau (84/185) d (84/184) e | OR | 95% CI | S.E | P‐value | OR | 95% CI | S.E | P‐value |
---|---|---|---|---|---|---|---|---|
Western | 1.36 | 1.02;1.80 | 0.14 | .04 | 1.43 | 1.02;2.01 | 0.17 | .04 |
Mediterranean/prudent | 0.97 | 0.75;1.26 | 0.13 | .83 | 0.94 | 0.71;1.26 | 0.15 | .68 |
High‐protein and alcohol | 0.92 | 0.71;1;20 | 0.13 | .54 | 0.71 | 0.51;0.98 | 0.17 | .04 |
High‐total and saturated fat | 1.11 | 0.87;1.43 | 0.13 | .40 | 1.10 | 0.84;1.45 | 0.14 | .50 |
P‐tau (14/255) d (14/254) e | OR | 95% CI | S.E | P‐value | OR | 95% CI | S.E | P‐value |
---|---|---|---|---|---|---|---|---|
Western | 0.89 | 0.51;1.57 | 0.29 | .69 | 0.87 | 0.44;1.73 | 0.35 | .87 |
Mediterranean/prudent | 0.92 | 0.54;1.59 | 0.28 | .78 | 0.74 | 0.40;1.36 | 0.31 | .33 |
High‐protein and alcohol | 0.97 | 0.56;1.67 | 0.28 | .90 | 0.93 | 0.49;1.76 | 0.33 | .82 |
High‐total and saturated fat | 1.42 | 0.86;2.34 | 0.26 | .17 | 1.40 | 0.79;2.48 | 0.29 | .26 |
Analyses in model 1 is unadjusted for confounders. Potential confounders that have been included in model 2 are: BMI, energy intake, sex, physical activity level, and educational level. One participant had missing physical activity level data.
Three participants had missing Aβ42/40 ratio values.
Aβ42+Tau stands for Aβ42 + total tau and/or phosphorylated tau pathology (n = 27). There were 22 participants with pathological Aβ42+total tau levels. The participants with pathological Aβ42+phosphorylated tau (n = 5) levels all had pathological total tau levels as well.
Number of participants with CSF biomarker pathology/number of participants who did not have pathological levels in the unadjusted model.
Number of participants with CSF biomarker pathology/number of participants who did not have pathological levels in the adjusted model.